419 related articles for article (PubMed ID: 9286277)
21. HSP-27 protein expression in uveal melanoma: correlation with predicted survival.
Jmor F; Kalirai H; Taktak A; Damato B; Coupland SE
Acta Ophthalmol; 2012 Sep; 90(6):534-9. PubMed ID: 21114636
[TBL] [Abstract][Full Text] [Related]
22. Proteomics of uveal melanomas suggests HSP-27 as a possible surrogate marker of chromosome 3 loss.
Coupland SE; Vorum H; Mandal N; Kalirai H; Honoré B; Urbak SF; Lake SL; Dopierala J; Damato B
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):12-20. PubMed ID: 19643972
[TBL] [Abstract][Full Text] [Related]
23. KI-67 immunopositivity in choroidal and ciliary body melanoma with respect to nucleolar diameter and other prognostic factors.
Al-Jamal RT; Kivelä T
Curr Eye Res; 2006 Jan; 31(1):57-67. PubMed ID: 16421020
[TBL] [Abstract][Full Text] [Related]
24. Ezrin as a prognostic indicator and its relationship to tumor characteristics in uveal malignant melanoma.
Mäkitie T; Carpén O; Vaheri A; Kivelä T
Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2442-9. PubMed ID: 11581181
[TBL] [Abstract][Full Text] [Related]
25. Uveal melanoma cell staining for CD34 and assessment of tumor vascularity.
Chen X; Maniotis AJ; Majumdar D; Pe'er J; Folberg R
Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2533-9. PubMed ID: 12147581
[TBL] [Abstract][Full Text] [Related]
26. Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-Met in uveal melanoma: an immunohistochemical study.
Mallikarjuna K; Pushparaj V; Biswas J; Krishnakumar S
Curr Eye Res; 2007 Mar; 32(3):281-90. PubMed ID: 17453948
[TBL] [Abstract][Full Text] [Related]
27. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma.
Mäkitie T; Summanen P; Tarkkanen A; Kivelä T
Invest Ophthalmol Vis Sci; 2001 Jun; 42(7):1414-21. PubMed ID: 11381040
[TBL] [Abstract][Full Text] [Related]
28. Increased HIF-1α expression correlates with cell proliferation and vascular markers CD31 and VEGF-A in uveal melanoma.
Mouriaux F; Sanschagrin F; Diorio C; Landreville S; Comoz F; Petit E; Bernaudin M; Rousseau AP; Bergeron D; Morcos M
Invest Ophthalmol Vis Sci; 2014 Mar; 55(3):1277-83. PubMed ID: 24481264
[TBL] [Abstract][Full Text] [Related]
29. Expression of cyclin-D1 in uveal malignant melanoma.
Errico ME; Staibano S; Tranfa F; Bonavolonta G; Lo Muzio L; Somma P; Lucariello A; Mansueto G; D'Aponte A; Ferrara G; De Rosa G
Anticancer Res; 2003; 23(3B):2701-6. PubMed ID: 12894561
[TBL] [Abstract][Full Text] [Related]
30. Circulating tumor cells as prognostic factor for distant metastases and survival in patients with primary uveal melanoma.
Schuster R; Bechrakis NE; Stroux A; Busse A; Schmittel A; Scheibenbogen C; Thiel E; Foerster MH; Keilholz U
Clin Cancer Res; 2007 Feb; 13(4):1171-8. PubMed ID: 17317826
[TBL] [Abstract][Full Text] [Related]
31. Routes of extraocular extension of uveal melanoma: risk factors and influence on survival probability.
Coupland SE; Campbell I; Damato B
Ophthalmology; 2008 Oct; 115(10):1778-85. PubMed ID: 18554722
[TBL] [Abstract][Full Text] [Related]
32. Matrix metalloproteinase-2 (MMP-2) immunoreactive protein--a new prognostic marker in uveal melanoma?
Väisänen A; Kallioinen M; von Dickhoff K; Laatikainen L; Höyhtyä M; Turpeenniemi-Hujanen T
J Pathol; 1999 May; 188(1):56-62. PubMed ID: 10398141
[TBL] [Abstract][Full Text] [Related]
33. Expression and distribution of MMPs and TIMPs in human uveal melanoma.
Lai K; Conway RM; Crouch R; Jager MJ; Madigan MC
Exp Eye Res; 2008 Jun; 86(6):936-41. PubMed ID: 18423620
[TBL] [Abstract][Full Text] [Related]
34. Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival?
Ramnath N; Tan D; Li Q; Hylander BL; Bogner P; Ryes L; Ferrone S
Cancer Immunol Immunother; 2006 Aug; 55(8):891-9. PubMed ID: 16187081
[TBL] [Abstract][Full Text] [Related]
35. Cytogenetics of uveal melanoma: a 7-year clinical experience.
Damato B; Duke C; Coupland SE; Hiscott P; Smith PA; Campbell I; Douglas A; Howard P
Ophthalmology; 2007 Oct; 114(10):1925-31. PubMed ID: 17719643
[TBL] [Abstract][Full Text] [Related]
36. Expression of classic and nonclassic HLA class I antigens in uveal melanoma.
Anastassiou G; Rebmann V; Wagner S; Bornfeld N; Grosse-Wilde H
Invest Ophthalmol Vis Sci; 2003 May; 44(5):2016-9. PubMed ID: 12714638
[TBL] [Abstract][Full Text] [Related]
37. Cripto-1 expression in uveal melanoma: an immunohistochemical study.
Mallikarjuna K; Vaijayanthi P; Krishnakumar S
Exp Eye Res; 2007 Jun; 84(6):1060-6. PubMed ID: 17412323
[TBL] [Abstract][Full Text] [Related]
38. Expression of COX-2 and prognostic outcome in uveal melanoma.
Cryan LM; Paraoan L; Hiscott P; Damato BE; Grierson I; Gray D; Farrell M; Doherty GA; Fitzgerald DJ; O'Brien C
Curr Eye Res; 2008 Feb; 33(2):177-84. PubMed ID: 18293189
[TBL] [Abstract][Full Text] [Related]
39. Clinical and cytogenetic analyses in uveal melanoma.
Kilic E; van Gils W; Lodder E; Beverloo HB; van Til ME; Mooy CM; Paridaens D; de Klein A; Luyten GP
Invest Ophthalmol Vis Sci; 2006 Sep; 47(9):3703-7. PubMed ID: 16936076
[TBL] [Abstract][Full Text] [Related]
40. Low prevalence of selective human leukocyte antigen (HLA)-A and HLA-B epitope losses in early-passage tumor cell lines.
Giacomini P; Giorda E; Fraioli R; Nicotra MR; Vitale N; Setini A; Delfino L; Morabito A; Benevolo M; Venturo I; Mottolese M; Ferrara GB; Natali PG
Cancer Res; 1999 Jun; 59(11):2657-67. PubMed ID: 10363989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
